NCT05804669 - A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2026

Conditions

Cushing SyndromeCushing DiseaseEctopic ACTH Syndrome

Interventions

DRUG

atumelnant

Atumelnant is an orally active investigational agent which antagonizes the action of ACTH at its receptor administered as oral tablets.

Trial Locations (1)

RECRUITING

National Institutes of Health (NIH) - National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda